Living donor liver transplantation for unresectable colorectal cancer liver metastases
10.12464/j.issn.1674-7445.2025223
- VernacularTitle:活体肝移植治疗不可切除结直肠癌肝转移
- Author:
Xiangyu ZHANG
1
;
Shiqiao LUO
1
;
Ao REN
1
Author Information
1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
- Publication Type:SystematicReview
- Keywords:
Living donor liver transplantation;
Colorectal cancer;
Liver metastases;
Unresectable;
Recurrence;
Hepatectomy;
Deceased donor liver transplantation;
Auxiliary liver transplantation
- From:
Organ Transplantation
2026;17(1):150-156
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the current status and outcomes of living donor liver transplantation (LDLT) in patients with unresectable colorectal cancer liver metastases (CRLM). Methods Two reviewers independently conducted a systematic search of Medline (via PubMed), the Cochrane Library, and ClinicalTrials.gov in accordance with preferred reporting items for systematic reviews guidelines. English-language publications reporting LDLT for unresectable CRLM were identified; study characteristics and recipient outcomes were extracted. Results Twelve studies were retrieved, six completed studies enrolling 55 patients and six ongoing trials. Selected patients appeared to derive benefit from LDLT. Reported overall survival was 100% at 1 year and 100%, 71.4% at 3 years. The 1-year progression-free survival was 85.7% and 75.1%, and 3-year progression-free survival was 68.6% and 53.7%. Conclusions Prospective data on LDLT for unresectable CRLM remain scarce. The approach is still investigational and warrants validation through prospective clinical trials.
